1. Home
  2. HQ vs BWAY Comparison

HQ vs BWAY Comparison

Compare HQ & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HQ

Horizon Quantum Holdings Ltd. Class A Ordinary Shares

N/A

Current Price

$10.25

Market Cap

585.9M

Sector

N/A

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

HOLD

Current Price

$13.88

Market Cap

572.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HQ
BWAY
Founded
2018
2003
Country
Singapore
Israel
Employees
44
129
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
585.9M
572.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HQ
BWAY
Price
$10.25
$13.88
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$13.25
AVG Volume (30 Days)
256.7K
148.7K
Earning Date
05-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$309.69
Revenue Next Year
N/A
$26.21
P/E Ratio
N/A
$81.98
Revenue Growth
N/A
N/A
52 Week Low
$8.29
$10.61
52 Week High
$14.65
$26.63

Technical Indicators

Market Signals
Indicator
HQ
BWAY
Relative Strength Index (RSI) 42.33 35.13
Support Level $9.38 $11.90
Resistance Level $10.40 $16.51
Average True Range (ATR) 1.56 0.52
MACD -0.16 -0.21
Stochastic Oscillator 8.25 2.12

Price Performance

Historical Comparison
HQ
BWAY

About HQ Horizon Quantum Holdings Ltd. Class A Ordinary Shares

Horizon Quantum Holdings Ltd is building software infrastructure to make quantum computers accessible to commercial enterprises and hardware providers. By bridging the gap between hardware and applications, the company seeks to equip developers, researchers, and enterprises with the quantum software infrastructure needed to solve real-world problems. The company is developing tools that can automatically accelerate code written for conventional computers on quantum computers.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: